Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey
Journal of Medical Case Reports 2012, 6:188 doi:10.1186/1752-1947-6-188Published: 9 July 2012
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It is widely used in the treatment of metastatic colorectal cancer. It has some specific side effects including severe bleeding, wound healing problems, gastrointestinal perforation, proteinuria and hypertension.
We present the case of a 65-year old Asian man with synovial metastasis of the knee who experienced intraarticular hemorrhage after bevacizumab treatment. He presented with monoarthritis of the left knee.
Bevacizumab-related hemorrhage can cause serious morbidity and unusual sites of hemorrhage may be seen.